Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer

Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer

TNBC is an aggressive cancer sub-type with limited treatment options and poor prognosis. New therapeutic targets are needed to improve outcomes in TNBC patients. PRCP is a lysosomal serine protease that cleaves peptide substrates when the penultimate amino acid is proline. A role for PRCP in TNBC or...

Full description

Bibliographic Details
Main Authors: Lei Duan, Sarah Calhoun, Ricardo E. Perez, Virgilia Macias, Fatima Mir, Melissa R. Pergande, Paolo Gattuso, Jeffrey A. Borgia, Carl G. Maki
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
prolylcarboxypeptidase
triple negative breast cancer
prognosis
receptor tyrosine kinases
G-protein coupled receptors
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/14/3/739

Internet

https://www.mdpi.com/2072-6694/14/3/739

Similar Items